Joss A W, Chatterton J M, Ho-Yen D O
Scottish Toxoplasma Reference Laboratory, Department of Microbiology, Raigmore Hospital, Inverness.
Public Health. 1990 Jan;104(1):9-20. doi: 10.1016/s0033-3506(05)80340-3.
We have reviewed the present day quantifiable cost to society of the 73 cases of congenital toxoplasmosis which are estimated to occur annually in Scotland with the cost of preventing the disease by screening and treatment. Our analysis includes advances in laboratory techniques. The cost of screening would depend on its scale and if in-house or commercial tests are used. If only 2 specimens were screened, at booking and at delivery, the screening costs are estimated to be between 0.5-0.9 times the preventable costs. If a third specimen were tested in the second trimester, to maximise scope for remedial action during pregnancy, the screening costs are 0.7-1.2 times preventable costs. As likely screening costs in most of the schemes we consider are now less than the preventable costs, a screening programme should be adopted.
我们回顾了目前苏格兰每年估计发生的73例先天性弓形虫病对社会造成的可量化成本，以及通过筛查和治疗预防该病的成本。我们的分析包括实验室技术的进展。筛查成本将取决于其规模以及使用的是内部检测还是商业检测。如果仅在预约时和分娩时对2份样本进行筛查，筛查成本估计为可预防成本的0.5至0.9倍。如果在孕中期检测第三份样本，以最大限度地扩大孕期采取补救措施的范围，筛查成本则为可预防成本的0.7至1.2倍。由于我们考虑的大多数方案中可能的筛查成本现在低于可预防成本，因此应采用筛查计划。
